We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended March 2025, Evolent Health (EVH - Free Report) reported revenue of $483.65 million, down 24.4% over the same period last year. EPS came in at $0.06, compared to $0.34 in the year-ago quarter.
The reported revenue represents a surprise of +4.76% over the Zacks Consensus Estimate of $461.69 million. With the consensus EPS estimate being $0.09, the EPS surprise was -33.33%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Average PMPM Fees / Revenue per Case - Performance Suite: $15.57 versus $16.14 estimated by three analysts on average.
Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.36 versus the three-analyst average estimate of $0.38.
Average PMPM Fees / Revenue per Case - Administrative Services: $15.72 compared to the $15.87 average estimate based on three analysts.
Average Lives on Platform / Cases - Cases: 14 thousand compared to the 14.88 thousand average estimate based on three analysts.
Average Lives on Platform / Cases - Performance Suite: 6.49 million versus 5.72 million estimated by three analysts on average.
Average Lives on Platform / Cases - Specialty Technology and Services Suite: 77.08 million compared to the 73.62 million average estimate based on three analysts.
Average Lives on Platform / Cases - Administrative Services: 1.21 million versus 1.2 million estimated by three analysts on average.
Average PMPM Fees / Revenue per Case - Cases: $2,947 versus the three-analyst average estimate of $2,957.33.
Total Revenue by product type- Performance Suite: $303.02 million versus $275.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -32.4% change.
Total Revenue by product type- Cases: $40.62 million compared to the $43.93 million average estimate based on three analysts. The reported number represents a change of -7.4% year over year.
Total Revenue by product type- Administrative Services: $57.19 million versus the three-analyst average estimate of $59.48 million. The reported number represents a year-over-year change of -2.4%.
Total Revenue by product type- Specialty Technology and Services Suite: $82.82 million versus $83.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7% change.
Shares of Evolent Health have returned +9% over the past month versus the Zacks S&P 500 composite's +13.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
For the quarter ended March 2025, Evolent Health (EVH - Free Report) reported revenue of $483.65 million, down 24.4% over the same period last year. EPS came in at $0.06, compared to $0.34 in the year-ago quarter.
The reported revenue represents a surprise of +4.76% over the Zacks Consensus Estimate of $461.69 million. With the consensus EPS estimate being $0.09, the EPS surprise was -33.33%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Average PMPM Fees / Revenue per Case - Performance Suite: $15.57 versus $16.14 estimated by three analysts on average.
- Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.36 versus the three-analyst average estimate of $0.38.
- Average PMPM Fees / Revenue per Case - Administrative Services: $15.72 compared to the $15.87 average estimate based on three analysts.
- Average Lives on Platform / Cases - Cases: 14 thousand compared to the 14.88 thousand average estimate based on three analysts.
- Average Lives on Platform / Cases - Performance Suite: 6.49 million versus 5.72 million estimated by three analysts on average.
- Average Lives on Platform / Cases - Specialty Technology and Services Suite: 77.08 million compared to the 73.62 million average estimate based on three analysts.
- Average Lives on Platform / Cases - Administrative Services: 1.21 million versus 1.2 million estimated by three analysts on average.
- Average PMPM Fees / Revenue per Case - Cases: $2,947 versus the three-analyst average estimate of $2,957.33.
- Total Revenue by product type- Performance Suite: $303.02 million versus $275.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -32.4% change.
- Total Revenue by product type- Cases: $40.62 million compared to the $43.93 million average estimate based on three analysts. The reported number represents a change of -7.4% year over year.
- Total Revenue by product type- Administrative Services: $57.19 million versus the three-analyst average estimate of $59.48 million. The reported number represents a year-over-year change of -2.4%.
- Total Revenue by product type- Specialty Technology and Services Suite: $82.82 million versus $83.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7% change.
View all Key Company Metrics for Evolent Health here>>>Shares of Evolent Health have returned +9% over the past month versus the Zacks S&P 500 composite's +13.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.